Pharmacologic Prevention of Incident Atrial Fibrillation | Zendy

Thomas A. Dewland | Zendy; Elsayed Z. Soliman | Zendy; José-Miguel Yamal | Zendy; Barry R. Davis | Zendy; Álvaro Alonso | Zendy; Christine M. Albert | Zendy; Lara M. Simpson | Zendy; L. Julian Haywood | Zendy; Gregory M. Marcus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacologic Prevention of Incident Atrial Fibrillation

Author(s) -

Thomas A. Dewland,

Elsayed Z. Soliman,

José-Miguel Yamal,

Barry R. Davis,

Álvaro Alonso,

Christine M. Albert,

Lara M. Simpson,

L. Julian Haywood,

Gregory M. Marcus

Publication year - 2017

Publication title -

circulation arrhythmia and electrophysiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.684

H-Index - 102

eISSN - 1941-3149

pISSN - 1941-3084

DOI - 10.1161/circep.117.005463

Subject(s) - lisinopril , medicine , chlorthalidone , hazard ratio , atrial fibrillation , amlodipine , cardiology , confidence interval , atrial flutter , randomized controlled trial , angiotensin converting enzyme , diuretic , blood pressure

Although atrial fibrillation (AF) guidelines indicate that pharmacological blockade of the renin-angiotensin system may be considered for primary AF prevention in hypertensive patients, previous studies have yielded conflicting results. We sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial surveillance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research